232 related articles for article (PubMed ID: 20708849)
1. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial.
Bral S; Gevaert T; Linthout N; Versmessen H; Collen C; Engels B; Verdries D; Everaert H; Christian N; De Ridder M; Storme G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1343-9. PubMed ID: 20708849
[TBL] [Abstract][Full Text] [Related]
2. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.
Schanne DH; Nestle U; Allgäuer M; Andratschke N; Appold S; Dieckmann U; Ernst I; Ganswindt U; Grosu AL; Holy R; Molls M; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Guckenberger M
Strahlenther Onkol; 2015 Feb; 191(2):125-32. PubMed ID: 25159135
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
[TBL] [Abstract][Full Text] [Related]
6. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
7. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.
Timmerman RD; Paulus R; Pass HI; Gore EM; Edelman MJ; Galvin J; Straube WL; Nedzi LA; McGarry RC; Robinson CG; Schiff PB; Chang G; Loo BW; Bradley JD; Choy H
JAMA Oncol; 2018 Sep; 4(9):1263-1266. PubMed ID: 29852037
[TBL] [Abstract][Full Text] [Related]
10. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.
Modh A; Rimner A; Williams E; Foster A; Shah M; Shi W; Zhang Z; Gelblum DY; Rosenzweig KE; Yorke ED; Jackson A; Wu AJ
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1168-76. PubMed ID: 25303891
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
[TBL] [Abstract][Full Text] [Related]
13. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
[TBL] [Abstract][Full Text] [Related]
14. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
Park HS; Harder EM; Mancini BR; Decker RH
J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
Fakiris AJ; McGarry RC; Yiannoutsos CT; Papiez L; Williams M; Henderson MA; Timmerman R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):677-82. PubMed ID: 19251380
[TBL] [Abstract][Full Text] [Related]
18. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.
Jain S; Poon I; Soliman H; Keller B; Kim A; Lochray F; Yeung L; Cheung P
Radiother Oncol; 2013 Aug; 108(2):320-5. PubMed ID: 23993401
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.
Temming S; Kocher M; Stoelben E; Hagmeyer L; Chang DH; Frank K; Hekmat K; Wolf J; Baus WW; Semrau R; Baues C; Marnitz S
Strahlenther Onkol; 2018 Feb; 194(2):91-97. PubMed ID: 28812120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
